Healthy Life

The pandemic has had a huge impact on transformation of biotechnological innovations. Russian scientists have already demonstrated their prowess to the global scientific and business communities when the first ever coronavirus vaccine Sputnik V was registered in August 2020. To become a ‘unicorn’ in biotechnology, a startup needs to offer the market an entirely new product or present a significant transformation of an existing one. In global practice, it is becoming common practice when biotechnological innovations are created in cooperation: science and market go for maximum partnership. Lately, large industrial corporations in Russia work together with biotechnology startups to create incubation and acceleration programmes for start-ups, tailored to the needs of the market. Using the opportunities provided by these accelerators, young scientists, guided by the industry, hone their entrepreneurial skills, develop innovative technologies under the auspices of medical clinics, learn to attract investment, and receive mentoring support from the experts.
● How can the existing start-ups be sustained in Russia, new ones grown, and what is needed to take Russian innovations to the international arena?
● What conditions need to be created for inflow of investment to biotechnological startups?
● What should the integration of government, universities, labs, and industrial partners be like?
● What do innovation startups focus on now?

Moderator
Pekka Viljakainen, Advisor to the Chairman of the Board of Directors, Skolkovo Foundation; Chairman, Aii Capital

Pekka Viljakainen

Advisor to the Chairman of the Board of Directors, Skolkovo Foundation; Chairman, Aii Capital

Mr. Pekka A. Viljakainen was born in Finland 1972. He studied engineering at the University of Technology in Lappeenranta. For 25 years worked as an ambassador between business executives and technology teams. He started as an entrepreneur in 1986, by establishing Oy Visual Systems Ltd. (1986-2004). His company was merged with TietoEnator in 2000. Mr. Viljakainen is widely known by his nickname, Bulldozer. The nickname was earned by his reputation and track record for handling very complex governance and political topics inside large international organizations. During his corporate carrier he acted as trusted advisor for CEO’s and chairman’s specializing for the transformation related to enterprise digitalization and HR.
After 26 years of his active Visual Systems-Tieto carrier, he left from operative roles on 2011 and focused to his non-profit leadership education project called www.nofear-community.com . Because of this he has been visiting speaker and advisor for several international corporations and faculties (like IMD Business School).
Since 2012 Mr Viljakainen is acting as senior advisor for the president of Skolkovo Foundation. Since that among other directions of work, he has been acting as a founder and advisor for several nationwide entrepreneurship programs in Russian Federation. Startup Tour Open Innovations 2013-2018 (over 85 cities of Russia and CIS) and international conference Startup Village 2013-2018. During those programs he has build a strong network of entrepreneurs, local governmental institutions as well as universities across Russia and abroad.
Mr Viljakainen is the member of Strategic Board of the Russian Postal Service and member of the Supervisory Board of PAO “Pochta Bank”. Chairman of the Board of ‘’Skolkovo – Venture Investments’’, Chairman of the Board “ZYFRA”.
Mr Viljakainen is also known as investor, business angel and advisor for several high-tech companies. Those activities are handled thru his family investment office called www.Aii.fi
He is also well known supporter and philanthropic for several areas related to education, classical music as well as several social projects. His hobbies are helicopter flying PPL(H), cross country skiing, weight lifting and triathlon.

Panellists
Arkady Dvorkovich, Chairman, Skolkovo Foundation
Natalia Komarova, General Director, Rusatom Healthcare
Igor Korobko, Head of Science and Innovative Development of Health Department, Ministry of Health of the Russian Federation (online)
Dmitry Kudlay, General Director, Generium
Sophie Park, Chief Strategy Officer, Bayer G4A (online)
Robert Scott, Head of Product & Portfolio, Novartis Biome (online)
Evgeny Shlyakhto, Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"

Arkady Dvorkovich

Chairman, Skolkovo Foundation

Born on May 26, 1972 in Moscow.
In 1994 graduated from Moscow State University with a Master degree in economics.
1994-1997 – worked as an expert in the Expert Group of Russia’s Ministry of Finance.
1997-2000 - Head of the Economic Expert Group of Russia’s Ministry of Finance.
Since August of 2000 – Adviser of the Minister of Economic Development and Trade.
Since 2001 - Deputy Minister of Economic Development and Trade.
Since April of 2004 - Head of the Presidential Experts’ Directorate of the Presidential Executive Office.
Since May 13, 2008 - Aide to the President.
From May 13, 2008 to May, 21 2012 served as an aide to the President of the Russian Federation.
On December 31, 2009 according to the decree of the President Dmitry Medvedev entered the working group for creation of a detached territorial complex for research and development and further commercialization of the results.
On May 21, 2012 he was appointed the Deputy Prime-Minister of the Russian Federation.
May 2018 – appointed co-chair of the Skolkovo Foundation council.
In September 2018, he was appointed to a government commission on modernising Russia’s economy and innovative development.
The same month, he was appointed Chair of the Skolkovo Foundation.

Igor Korobko

Head of Science and Innovative Development of Health Department, Ministry of Health of the Russian Federation

Dmitry Kudlay

General Director, Generium

MD, professor
Academic background
University: Medical University, Novosibirsk
Department and Qualification: General medicine, doctor
Professional background
1996 - 1999 – Director, the hospital of the Ministry of Internal Affairs, Novosibirsk
2000 - 2004 – Managing positions in Marketing & Promotion, Russian pharmaceutical industry
2004 - 2013 – Deputy General Director (Marketing & Promotion), PHARMSTANDARD (the largest Russian pharmaceutical company)
2013 - present – General director, GENERIUM
Membership and Awards
• Member of the Government Subcommittee on the Circulation of Medicines
• Member of the working group on the Eurasian Economic Commission drug market, MoH
• Member of the Expert Council for the Development of Pharmaceutical and Medical Industry, Ministry of Industry and Trade
• Member of European Respiratory Society
• Winner of the Russian Federation Government Award
Dmitry Kudlay is the author of more than 70 scientific articles in peer-reviewed Russian and foreign publications.

Evgeny Shlyakhto

Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"

Professor Evgeny Shlyakhto, Director General of the Almazov National Medical Research Centre, Academician of the Russian Academy of Science, President of the Russian Society of Cardiology, Fellow of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology.
Professor Shlyakhto was born on June 29, 1954 in Pogar, the Bryansk region. He graduated from the Pavlov Medical University in Saint Petersburg in 1977 and became Doctor of Science in Medicine in 1992, Professor in 1994, Honored Russian Scientist in 2004, and Academician of the Russian Academy of Sciences in 2014.
Evgeny Shlyakhto has been the Director General of the Almazov National Medical Research Centre since 2001 and the President of the Russian Society of Cardiology since 2011. In 2010, he became a member of the WHO Expert Working Group.
The Centre led by Prof. Shlyakhto carries out intensive research in the fields of translational medicine, molecular diagnostics, development of diagnostic tools for personalized treatment, cellular and tissue engineering for therapeutic purposes, creation of biocompatible materials and tissue-engineered constructs designed to create breakthrough medical technologies of fundamental importance for providing high-tech care to patients with cardiovascular, endocrine and blood diseases.
The results of research work by Prof. Shlyakhto have been summarized in more than 800 publications, 16 inventions, 2 scientific discoveries, and a number of monographs. Prof. Shlyakhto was a supervisor in 57 PhD and 20 DSc students..
Professor Shlyakhto is a member of the Presidium of the Russian Academy of Science, the Presidential Council for Science and Education, the Regional Health Council under the Federation Council of the Russian Federal Assembly, the Expert Health Council of the Federation Council Committee on Social Policy of the Russian Federal Assembly, Vice President of the National Medical Chamber.
Evgeny Shlyakhto is the Editor-in-Chief of the following medical journals: Russian Journal of Cardiology, Translational Medicine, and Journal of Arrhythmology. He also is a member of the international editorial board of the European Heart Journal.
Professor Shlyakhto plays an active role in such international committees as the ESC Congress Programme Committee (since 2012) and of the ESC Committee for Practice Guidelines (since 2015).
Evgeny Shlyakhto received the Russian Federation Government Prize in science and technology in 2009 and won the Pavlov Award, the prize for scientific and technological achievement in Physiology and Medicine from the Saint Petersburg Government and St. Petersburg Scientific Center of the Russian Academy of Sciences, in 2011. He received an Order of Honour in 2012 and 4th class Order of Merit for the Motherland in 2017.

Front row participants
Noor Jandali, Analyst, Droobi Health, Qatar
Sergei Sorokin, CEO, Botkin.AI
Vadim Tarasov, Director, Institute of Translational Medicine and Biotechnology

Sergei Sorokin

General Director, Intellogic LLC; Founder, Botkin.AI

Has more than 10 years of experience in the field of information technology in healthcare. As the director of the healthcare division in Rostelecom PJSC, S. Sorokin took part in the development of services within the Unified State Healthcare Information System of the Russian Federation and other healthcare IT projects in Russia and abroad.
Since 2015, he has been the founder and CEO of the Russian company Intellogic LLC, currently developing the TeleMD platform project for diagnosing diseases with use of artificial intelligence. The company utilizes a unique technology to build AI-based mathematical patient representation models, allowing doctors to analyze the risks of various diseases (including cancer) and to perform their early diagnostics and detection.